Alphalyse has pioneered the use of mass spectrometry analysis since 2002. Our scientists have completed over 10,000 protein characterization analyses, including forced degradation studies and more than 600 LC-MS-based residual/host cell protein projects. As a specialist contract research organization (CRO), we offer protein analysis services to support biopharmaceutical companies in developing and manufacturing patient-safe products such as mAbs, vaccines, recombinant proteins, and cell & gene therapies. You can count on us to work closely with you on developing well-characterized biologics by challenging and improving analysis methods using top-of-the-line mass spectrometry technology (LC-MS). Our comprehensive reports will allow you to carry out data-driven process development and regulatory documentation under ICH Q6B guidelines.